ARS Pharmaceuticals, Inc.
SPRY
$9.72
-$0.08-0.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,043.40% | -- | -- | -- | 4,900.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,043.40% | -- | -- | -- | 4,900.00% |
| Cost of Revenue | 30.79% | -22.70% | 14.34% | 51.07% | -4.33% |
| Gross Profit | 204.72% | 175.03% | 2,529.17% | 17.82% | 11.14% |
| SG&A Expenses | 507.25% | 416.51% | 420.26% | 28.75% | -33.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 299.82% | 242.25% | 285.14% | 32.47% | -23.16% |
| Operating Income | -210.39% | -181.81% | 561.54% | -20.97% | 25.54% |
| Income Before Tax | -258.60% | -229.77% | 800.64% | -28.67% | 27.94% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -258.60% | -229.77% | 796.62% | -28.67% | 27.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -258.60% | -229.77% | 796.62% | -28.67% | 27.94% |
| EBIT | -210.39% | -181.81% | 561.54% | -20.97% | 25.54% |
| EBITDA | -208.93% | -179.93% | 562.37% | -20.99% | 25.56% |
| EPS Basic | -252.90% | -224.37% | 787.27% | -26.75% | 29.34% |
| Normalized Basic EPS | -252.97% | -187.80% | 640.48% | -26.75% | 29.37% |
| EPS Diluted | -252.90% | -224.37% | 663.67% | -26.75% | 29.34% |
| Normalized Diluted EPS | -252.97% | -187.80% | 541.52% | -26.75% | 29.37% |
| Average Basic Shares Outstanding | 1.58% | 1.63% | 1.32% | 1.52% | 2.02% |
| Average Diluted Shares Outstanding | 1.58% | 1.63% | 24.01% | 1.52% | 2.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |